REVVITY INC (RVTY) Stock News
NYSE:RVTY - New York Stock Exchange, Inc. - US7140461093 - Common Stock - Currency: USD
RVTY Latest News, Press Relases and Analysis
Stay informed with the top movers within the S&P500 index on Wednesday.
Curious about the S&P500 stocks that are in motion on Wednesday? Join us as we explore the top movers within the S&P500 index during today's session.
What's going on in today's session: S&P500 movers
Uncover the latest developments among S&P500 stocks in today's session. Stay tuned to the S&P500 index's top gainers and losers on Wednesday.
3 Mid-Cap Stocks with Questionable Fundamentals
Many investors pay attention to mid-cap stocks because they have established business models and expansive market opportunities. However, their paths to becoming $100 billion corporations are ripe with competition, ranging from giants with vast resources to agile upstarts eager to disrupt the status quo.
S&P 500 Gains & Losses Today: Supermicro Stock Surges After DataVolt Deal
The S&P 500 ticked 0.1% higher on Wednesday, May 14, 2025, bolstered by a tech sector rally even as macroeconomic concerns pressured other sectors.
Which S&P500 stocks are gapping on Wednesday?
Wondering which stocks are making significant price gaps? Explore the S&P500 index on Wednesday to find the gap up and gap down stocks in today's session.
Repligen, Bruker, Agilent, Medpace, and Revvity Shares Skyrocket, What You Need To Know
A number of stocks jumped in the afternoon session after the major indices popped (Nasdaq +3.4%, S&P 500 +2.5%) in response to the positive outcome of U.S.-China trade negotiations, as both sides agreed to pause some tariffs for 90 days, signaling a potential turning point in ongoing tensions. This rollback cuts U.S. tariffs on Chinese goods to 30% and Chinese tariffs on U.S. imports to 10%, giving companies breathing room to reset inventories and supply chains.
Revvity to Present at Upcoming Investor Conferences
RVTY Rises as Q1 Earnings & Sales Beat Estimates, '25 Sales View Up
Revvity's first-quarter results showcase strong growth in Diagnostics business, along with recovery in Life Sciences segmental sales.
Biotech Firm Revvity Reports Better-Than-Expected Earnings
Revvity reported first-quarter earnings that topped analysts' estimates.
Revvity (RVTY) Q1 Earnings: How Key Metrics Compare to Wall Street Estimates
While the top- and bottom-line numbers for Revvity (RVTY) give a sense of how the business performed in the quarter ended March 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Revvity Q1 Earnings Surpass Street Estimates, Investors Cheer 2025 Revised Revenue Guidance
For the full year, Revvity raised its revenue guidance to a range of $2.83 billion to $2.87 billion to reflect recent changes in foreign currency exchange rates.
BetMGM swings to profit in first quarter amid e-betting surge
The company has been pushing to grow its online presence and capitalise on the booming e-betting market amid stiff competition. Its online sports division reported a 68% revenue growth despite unfavourable sports outcomes during key moments in the quarter. Shares of Entain were up 5.3% at 619.4 pence by 1122 GMT, while MGM was up 0.4%.
Revvity joins peers Thermo Fisher, Danaher in tariff warning, maintains profit outlook
(Reuters) -Medical equipment maker Revvity on Monday joined larger peers in warning about the impact of tariffs imposed by the U.S. President Donald Trump's administration, but maintained its annual profit outlook. Revvity anticipates a $135 million impact from tariffs on China; however, plans cost-saving measures and expects to benefit from a weaker dollar due to generating more than half its revenue outside the U.S. The warnings came after Revvity posted first-quarter results above Wall Street estimates on steady demand for tools used in medical research.
Taiwan's Inventec to invest up to $85 million in US to lessen tariff impact
TAIPEI (Reuters) -Taiwanese contract electronics manufacturer Inventec has agreed to invest up to $85 million to build manufacturing facilities in Texas to help mitigate the impact of U.S. tariffs, it said on Monday. In a statement to the Taiwan stock exchange, the company said that its U.S. subsidiary would look for "suitable production" plants in the southwestern U.S. state. The plan has been agreed upon by the board to "meet customer shipment location requirements, actively pursue new customers and markets, and mitigate the impact of fluctuations in U.S. tariff policies," the company said in its short statement.
Revvity (RVTY) Beats Q1 Earnings and Revenue Estimates
Revvity (RVTY) delivered earnings and revenue surprises of 5.21% and 0.39%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Mentions: BDSX
Morning Bid: The toll from Trump's tariffs
* U.S. Treasury Secretary Scott Bessent says he does not back President Donald Trump's assertion that tariff talks with China are under way. * Trump urges Russia to stop its attacks in Ukraine and suggests Ukrainian President Volodymyr Zelenskiy is ready to give up Crimea as the price of a peace deal with Russia. * Risks are high the global economy will slip into a recession this year, according to a majority of economists in a Reuters poll.
Revvity Announces Financial Results for the First Quarter of 2025
Revvity Board Declares Quarterly Dividend
Analysts Estimate Bausch + Lomb (BLCO) to Report a Decline in Earnings: What to Look Out for
Bausch + Lomb (BLCO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Mentions: BLCO
Revvity to Hold Earnings Call on Monday, April 28, 2025
Revvity Secures FDA Approval for Improved Automated Latent Tuberculosis Test
How Tariffs Are Rocking The 'Bubblegum And Shoestring' Medical Supply Chain
Uncertainty has cast a pall over medical stocks, which are taking a "wait-and-see" approach to Trump's tariffs.